«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2009年第3期

页码:

397-399,406

栏目:

临床研究

出版日期:

2009-05-15

文章信息/Info

Title:

Effects of atorvastain and rosiglitazone on tumor necrosis factor-alpha synthesis

作者:

吴旭斌¹; 周胜华²; 伍广伟¹; 刘启明²; 林英忠¹; 胡昌兴¹

1.广西壮族自治区人民医院心内科,广西 南宁 530021;2.中南大学湘雅二院心血管内科，湖南 长沙 410011

Author(s):

WU Xu-bin¹;  ZHOU Sheng-hua²;  WU Guang-wei¹;  LIU Qi-ming²;  LIN Ying-zhong¹;  HU Chang-xing¹

1.Department of Cardiology, People’s Hospital, Guangxi Zhuangzu Autonomous Region, Nanning 530021, Guangxi, China; 2.Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

关键词:

急性冠脉综合征; 阿托伐他汀; 罗格列酮; 肿瘤坏死因子α

Keywords:

acute coronary syndrome;  atorvastain;  rosiglitazone;  tumor necrosis factor-alpha

分类号:

R541.4

DOI:

-

文献标识码:

A

摘要:

目的 研究罗格列酮联合阿托伐他汀干预对无糖尿病的急性冠脉综合征（ACS）患者外周血单核细胞分泌肿瘤坏死因子α（TNF-α）的影响。方法 分离无糖尿病的ACS患者外周血单核细胞，设置对照组（等容积的二甲基亚砜）、阿托伐他汀（1 μmol/L）组、罗格列酮（1 μmol/L）组及二者联合组（阿托伐他汀1 μmol/L加罗格列酮1 μmol/L组） 4个组，分别与所分离的外周血单核细胞共同孵育24 h后，用夹心酶联免疫吸附测定法检测细胞培养上清液TNF-α，用逆转录聚合酶链反应（RT-PCR）测定TNF-α mRNA的表达。结果 与对照组相比较，阿托伐他汀组、罗格列酮组及联合组对无糖尿病ACS患者外周血单核细胞分泌TNF-α［分别为(229±24)ng/L、(236±28)ng/L、(159±29)ng/L vs (306±40)ng/L，均P<0.05］及TNF-α mRNA的相对半定量吸光值（A）比值（分别为0.35±0.12,0.39±0.11,0.26±0.06 vs 0.78±0.14，均P<0.05）均降低，且罗格列酮联合阿托伐他汀组比阿托伐他汀组、罗格列酮组降低更显著（均P<0.05）。结论 阿托伐他汀和罗格列酮都可通过降低无糖尿病的ACS患者外周血单核细胞产生分泌TNF-α，发挥阿托伐他汀和罗格列酮的抗炎作用，且二者联合干预具有协同作用,防治效果更佳。

Abstract:

AIM To investigate the effects of atorvastatin and rosiglitazone on the synthesis of tumor necrosis factor-alpha in peripheral blood monocytes from patients with acute coronary syndrome without diabetes mellitus. METHODS Monocytes were isolated from patients with acute coronary syndrome without diabetes mellitus and cultured with dimethyl sulphoxide (as the control), atorvastatin (1 μmol/L), and rosiglitazone (1 μmol/L), or atorvastain (1 μmol/L) plus rosiglitazone (1 μmol/L) for up to 24 hours. Tumor necrosis factor-alpha antigens in supernatant were measured by enzyme-linked immunosorbent assay and their mRNA levels were assessed by reverse-transcriptase polymerase chain reaction. RESULTS Compared with the control, atorvastatin (1 μmol/L), and rosiglitazone (1 μmol/L), or atorvastain (1 μmol/L) plus rosiglitazone (1 μmol/L) decreased the levels of tumor necrosis factor-alpha protein ［(229±24)ng/L, (236±28)ng/L, (159±29)ng/L, vs (306±40)ng/L, respectively, all P<0.05］, and their mRNA (0.35±0.12, 0.39±0.11, 0.26±0.06 vs 0.78±0.14, respectively, all P<0.05) in peripheral blood monocytes from patients with acute coronary syndrome without diabetes mellitus. Furthermore, Compared with the groups of atorvastatin (1μmol/L) or rosiglitazone (1μmol/L), the groups of atorvastain plus rosiglitazone resulted in more significant reduction (P<0.05). CONCLUSION Both atorvastatin and roiglitazone, assuage inflammation through reducing tumor necrosis factor-alpha in peripheral blood monocytes from patients with acute coronary syndrome. Synergistic administration of atorvastatin and roiglitazone exerts better preventive and therapeutic effects on acute coronary syndrome.

参考文献/References

[1］ Adamiec R, Gacka M, Dobosz T, et al. Stimulation of the peroxisome proliferator-activated receptor gamma (PPAR gamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy［J］. Atherosclerosis, 2007， 194(2):e108-e115.

［2］ Nagata K, Ishibashi T, Sakamoto T, et al. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes［J］. J Hypertens, 2001, 19(4):775-783.

［3］ Sidhu JS, Cowen D, Kaski JC. The effects of rosiglitazone, a PPARgamma agonist, on markers of endothelial cell activation, C- reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients［J］. J Am Coll Cardiol, 2003, 42(10):1757-1763.

［4］ Sidhu JS, Cowan D, Tooze JA, et al. Peroxisome proliferator-activated receptor-［gamma］ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease［J］. Am Heart J, 2004, 147(6):e25.

［5］ Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus［J］. Am J Cardiol, 2004, 94(2):151-156.

［6］ Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus［J］. Arterioscler Thromb Vasc Biol, 2004, 24(5):930-934.

［7］ Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation［J］. Cardiovasc Res, 2005, 65(4):907-912.

备注/Memo

备注/Memo:

收稿日期：2008-11-18.作者简介：吴旭斌，主治医师，博士Email:xubinwu@hotmail.com

常用功能

更新日期/Last Update: 2009-05-18